drugset / Trial / NCT01825798

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

NCT01825798 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether metformin is safe and effective in the treatment of weight or weight gain in young people with Autism Spectrum Disorders (ASD) who are currently taking atypical antipsychotic medication.

Timeline

Start
2013-04
Primary completion
2015-06
Completion
2015-10

Outcome

Met primary endpoint

paper Metformin reduced BMI z scores from baseline to week 16 significantly more than placebo PMID 27556593 ↗

paper difference in 16-week change scores vs placebo, -0.10 [95% CI, -0.16 to -0.04]; P = .003 PMID 27556593 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject Metformin Small molecule 850 mg Oral